Atopiclair™: its position within a topical paradigm for the treatment of atopic dermatitis

References

• Abramovits W. A clinician’s paradigm in the treatment of atopic dermatitis. J. Am. Acad. Dermatol.53, S70–S77 (2005).
   Web of Science ®Google Scholar
• Abramovits W, Goldstein A, Stevenson L. Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis. Clin. Dermatol.21(5), 383–391 (2003).
   PubMed Web of Science ®Google Scholar
• Abramovits W. Atopic dermatitis. J. Am. Acad. Dermatol.53, S86–S93 (2005).
   PubMed Web of Science ®Google Scholar
• Williams H, Robertson C, Stewart A et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J. Allergy Clin. Immunol.103, 125–138 (1999).
   PubMed Web of Science ®Google Scholar
• Goldstein AM, Abramovits W. Ceramides and the stratum corneum: structure, function and new methods to promote repair. Int. J. Dermatol.42(4), 256–259 (2003).
   PubMed Web of Science ®Google Scholar
• Cornell RC, Stoughton RB. Correlation of vasoconstrictor assay and clinical activity in psoriasis. Arch. Dermatol.121, 63–67 (1985).
   PubMed Web of Science ®Google Scholar
• Cook D. Rx topical corticosteroids HPA axis suppression and cutaneous effects. FDA Nonprescription Drugs Advisory Committee (NDAC) and the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC), March 24 (2005).
   Google Scholar
• Van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology197, 31–36 (1998).
   PubMed Web of Science ®Google Scholar
• Fowler J. Pimecrolimus, a topical calcineurin inhibitor for atopic dermatitis and other inflammatory skin diseases. Expert Rev. Dermatol.1(3), 343–354 (2006).
   Google Scholar
• Reitamo S, Harper J, Bos JD et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br. J. Dermatol.150, 554–562 (2004).
   PubMed Web of Science ®Google Scholar
• Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br. J. Dermatol.153, 701–705 (2005).
   PubMed Web of Science ®Google Scholar
• Harper J, Smith C, Rubins A et al. A multicenter study of the pharmokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J. Invest. Dermatol.124, 695–699 (2005).
   PubMed Web of Science ®Google Scholar
• Koo JY, Fleischer A, Pariser D et al. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7,000 patients) open-label study. American Academy of Dermatology Conference. March 21–26, CA, USA, P22 (2003).
   Google Scholar
• Koo JY, Fleisher A, Abramovits W et al. Tacrolimus is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J. Am. Acad. Dermatol.53, S195–S205 (2005).
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol.46(4), 495–504 (2002).
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics110(1 Pt 1), e2 (2002).
   PubMed Web of Science ®Google Scholar
• Abramovits W, Perlmutter A. Steroids vs. other immune modulators in the management of allergic dermatoses. Curr. Opin. Allergy Clin. Immunol.6(5), 345–354 (2006).
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm. Venereol. (Suppl. 92), 44–47 (1980).
   Web of Science ®Google Scholar
• Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm. Venereol. Suppl. (Stockh).144, 13–14 (1989).
   PubMedGoogle Scholar
• Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS036DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J. Drugs Dermatol.5(3), 236–244 (2006).
   PubMedGoogle Scholar
• Zhai H, Villarama C, Hafeez Z et al. Efficacy of a topical agent, MAS063D (Atopiclair), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis: a double-blind, vehicle-controlled study. Exog. Dermatol.2, 301–330 (2003).
   Google Scholar
• Cimaz R. Efficacy and safety of atopiclair in pediatric dermatoses: preliminary findings from an open pilot study. Poster Presentation AIDA National Congress. Genova, Italy, June (2005).
   Google Scholar
• Abramovits W, Gover M, Gupta A. Atopiclair nonsteroidal cream. Skinmed4(6), 369 (2005).
   PubMedGoogle Scholar
• Belloni G, Pinelli S, Veraldi S. A randomized, double-blind, vehicle controlled study to evaluate the efficacy and safety of MAS063DP (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur. J. Dermatol.15, 31–36 (2005).
   PubMed Web of Science ®Google Scholar
• Monder C, White PC. 11 beta hydroxysteroid dehydrogenase. Vitam. Horm.47, 187–271 (1993).
   PubMed Web of Science ®Google Scholar
• MacKenzie MA, Hoefnagels WH, Jansen RW, Benraad TJ, Kloppenborg PW. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy volunteers. J. Clin. Endocrinol. Metab.70(6), 1637–1643 (1990).
   PubMed Web of Science ®Google Scholar
• Grassi L, Moretti M, Bisetti A. Un nuovo farmaco mucoattivo con attivita’ anti-proteasica: la Telmesteina. Riv. Ital. Biol. Med.12, 67–74 (1992).
   Google Scholar
• Data on file. Sinclair Pharmaceuticals, March 2005.
   Google Scholar
• Cristoni A, Di Pierro F, Morazzoni P et al. Procyanidines from Vitis vinifera L. and protection against UV-photo damages. Acta Phytotherapeutica1, 52–56 (1998).
   Google Scholar
• Maffei Facino R, Carini M, Aldini G, Calloni MT, Bombardelli E, Morazzoni P. Sparing effect of procyanidins from Vitis vinifera on vitamin E: in vitro studies. Planta Med.64(4), 343–347 (1998).
   PubMed Web of Science ®Google Scholar
• Data on file from manufacturer, Seppic S.A 2001.
   Google Scholar